Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.
about
Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future DirectionsCeritinib: A primer for pharmacists.Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance statusInsights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.Alectinib for treatment of ALK-positive non-small-cell lung cancer.Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements.Alectinib-a new chapter in the management of ALK-positive lung cancer.Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinibLeptomeningeal disease: current diagnostic and therapeutic strategies.Leptomeningeal metastasis from systemic cancer: Review and update on management.Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
P2860
Q26741320-F9B65BB9-43A9-4089-81FB-60A6BA907420Q30244613-AED3B86B-0D7B-4C3A-B6CF-914DFC8CAFFAQ33760992-BF1ABEEB-18E7-4ED3-8019-AC5A45EFD30CQ36322851-F2510836-669D-4190-870B-49F2E83A550BQ36550838-99CE96DF-8506-40C9-B25D-57C5205C5561Q38459398-77D3B56D-2C56-4D5B-AFFC-DB9CE32CA1D7Q38805618-E499929D-FCF6-4AE3-9578-35D7BFBA626AQ38816270-7A655509-8E77-4AC6-B910-A489859764C0Q42344252-17DCFE2D-5C8C-4962-9A18-13C5094E6CE1Q42359754-893D7FA6-E769-4F8E-9DF1-0EC897E80D05Q42434572-ADBA625C-E4F6-45E5-8C57-673D1ECFCCB1Q42673256-78ADFB15-9614-4DEF-AEBF-2E2C881B5985Q42700664-785BDC40-F54E-4351-A750-7F4372089D19Q47428678-9933447B-12CB-45BB-AD21-C92ED5000D6BQ58802261-DC8B094E-C3FE-4CD7-9F79-46DB78FA4A2D
P2860
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Alectinib induces a durable (> ...... leptomeningeal carcinomatosis.
@ast
Alectinib induces a durable (> ...... leptomeningeal carcinomatosis.
@en
type
label
Alectinib induces a durable (> ...... leptomeningeal carcinomatosis.
@ast
Alectinib induces a durable (> ...... leptomeningeal carcinomatosis.
@en
prefLabel
Alectinib induces a durable (> ...... leptomeningeal carcinomatosis.
@ast
Alectinib induces a durable (> ...... leptomeningeal carcinomatosis.
@en
P2093
P2860
P1433
P1476
Alectinib induces a durable (> ...... leptomeningeal carcinomatosis.
@en
P2093
Edward B Garon
Karen R Sommers
Michele C Azada
P2860
P304
P356
10.1634/THEONCOLOGIST.2014-0309
P577
2015-01-07T00:00:00Z